US Sales Of Sinclair Pharma's Silhouette InstaLift-Off
Executive Summary
Aesthetics company Sinclair Pharma has reported headline growth of 51% in 2016 due to strong unexpected interest for its Silhouette Instalift product.
You may also be interested in...
Investor Eye: Howard Rowe, Hayfin Capital Management – The Specialized Health Care Lenders
In this edition of Investor Eye, Medtech Insight meets with Howard Rowe, managing director and head of health care at Hayfin Capital Management, a $17bn international asset management firm headquartered in London.
Sinclair Pharma Bullish About Profitability By Year-End
Encouraged by its solid sales performance in the first half of this year, UK aesthetics company Sinclair Pharma is optimistic it can close out 2017 with a small profit. The firm's H1 revenues were boosted by continued growth in key markets, leading to a 16% top-line growth.
Sinclair Pharma's Non-Surgical Facelift Gains Access To US Market Via Thermigen Deal
Sinclair Pharma has gained access to the world’s largest aesthetics market by enlisting Thermigen as the exclusive US distributor of Silhouette InstaLift, a non-surgical alternative to facelifts.